Cancer growth and spread are saltatory and phase-locked to the reproductive cycle through mediators of angiogenesis

Molecular Cancer Therapeutics

Volumn 4, Issue 7, 2005, Pages 1065-1075

  Wood, Patricia A ^a,b   Bove, Kathleen ^d   You, Shaojin ^a,b   Chambers, Ann ^e   Hrushesky, William J M ^a,b,c  

^a WJB Dorn VA Medical Center   (United States)

^b UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF SOUTH CAROLINA   (United States)

^d STRATTON VA MEDICAL CENTER   (United States)

^e LONDON REGIONAL CANCER PROGRAM   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLCHOLANTHRENE; BASIC FIBROBLAST GROWTH FACTOR; CD31 ANTIGEN; SEX HORMONE; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; BLOOD VOLUME; BREAST CANCER; CANCER GROWTH; CARCINOGENESIS; CONTROLLED STUDY; DENSITY; DIESTRUS; FEMALE; FREQUENCY ANALYSIS; GENE EXPRESSION; GROWTH RATE; MASTECTOMY; MENSTRUAL CYCLE; METASTASIS POTENTIAL; MOUSE; MOUSE STRAIN; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; PROESTRUS; PROTEIN LOCALIZATION; REGULATORY MECHANISM; TISSUE DISTRIBUTION;

ANIMALS; BLOOD VESSELS; CAPILLARY PERMEABILITY; ESTROUS CYCLE; FEMALE; FIBROBLAST GROWTH FACTOR 2; GONADAL STEROID HORMONES; MALE; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, ANIMAL; METHYLCHOLANTHRENE; MICE; MICE, INBRED STRAINS; NEOVASCULARIZATION, PATHOLOGIC; OVARIECTOMY; REFERENCE VALUES; RNA, MESSENGER; SARCOMA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 23144461659     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0028     Document Type: Article

References (52)

1. Wood PA, Hrushesky WJM. Sex cycle modulates cancer growth. Breast Cancer Res Treat 2005;91:95-102.
2. Hrushesky WJM. Rhythmic menstrual cycle modulation of breast cancer biology. J Surg Oncol 2000;74:238-41.
3. Bove K, Lincoln DW, Wood PA, Hrushesky WJM. Fertility cycle influence on surgical breast cancer cure. Breast Cancer Res Treat 2002; 75:65-72.
4. Ratajczak HV, Sothern RB, Hrushesky WJM. Estrous influence on surgical cure of a mouse breast cancer. J Exp Med 1988;168:73-83.
5. Hrushesky WJM, Bluming AZ, Gruber SA, Sothern RB. Menstrual influence on surgical cure of breast cancer. Lancet 1989;334:949-52.
6. Fentiman IS, Gregory WM, Richards MA. Effects of menstrual phase on surgical treatment of breast cancer. Lancet 1994;344:402.
7. Bluming AZ, Hrushesky WJM. The effect of surgical timing within the fertility cycle on breast cancer outcome. Ann N Y Acad Sci 1991;618: 277-91.
8. Senie RT, Tenser SM. The timing of breast cancer surgery during the menstrual cycle. Oncology 1997;10:1509-17.
9. Jatoi I. Timing of surgery for primary breast cancer with regard to the menstrual cycle phase and prognosis. Breast Cancer Res Treat 1998;52: 217-25.
10. Badwe RA, Mittra I, Havalda R. Timing of surgery during the menstrual cycle and prognosis of breast cancer. J Biosci 2000;25: 113-20.
11. Saad Z, Bramwell V, Wilson S, O'Malley F, Jeacock J, Chambers A. Expression of genes that contribute to proliferative and metastatic ability in breast cancer resected during various menstrual phases. Lancet 1998; 351:1170-3.
12. Hrushesky WJM. Breast cancer, timing of surgery, and the menstrual cycle: call for prospective trial. J Womens Health 1996;5:555-65.
13. Love RR, Duc NB, Dinh NV, Shen T, Havighurst TZ, Allred DC. Mastectomy and oophorectomy by menstrual cycle phase in women with operable breast cancer. J Natl Cancer Inst 2002;94:662-9.
14. Hrushesky WJM. Mastectomy and oophorectomy by menstrual cycle phase in women with operable breast cancer (Love et al.)[letter to the editor]. J Natl Cancer Inst 2002;94:1720-1.
15. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;83:4-6.
16. Hyder SM, Nawaz Z, Chiappetta C, Stancel GM. Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor. Cancer Res 2000; 60:3183-90.
17. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for endothelial cells. Biochem Biophys Res Commun 1989;161:851-8.
18. Cullinan K, Koos RD. Expression of basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), and keratinocyte growth factor (KGF) in the rat uterus-stimulation by estrogen. Biol Reprod 1991;44 (Suppl 1):536.
19. Cullinan-Bove K, Koos RD. Vascular endothelial growth factor/vascular permeability factor expression in the rat uterus: rapid stimulation by estrogen correlates with estrogen-induced increases in uterine capillary permeability and growth. Endocrinology 1993;133: 829-37.
20. Toi M, Inada K, Suzuki H, Tominga T. Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. Breast Cancer Res Treat 1995;36:193-204.
21. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis: Correlation in invasive breast cancer. N Engl J Med 1991; 324:1-8.
22. Kim KJ, Bing L, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 1993;362:841-4.
23. Asano M, Yukita A, Matsumoto T, Kondo S, Suzuki H. Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor 121. Cancer Res 1995;55:5296-301.
24. Zhang H, Craft P, Scott PAE, et al. Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells. J Natl Cancer Inst 1995;87: 213-9.
25. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A 1996;93:14765-70.
26. Gospodaromicz D, Neufeld G, Schweigerer L. Fibroblast growth factor: Structural and biological properties. J Cell Physiol 1987;Suppl 5: 15-26.
27. Smith K, Fox S, Whitehouse R, et al. Upregulation of basic fibroblast growth factor in breast carcinoma and its relationship to vascular density, estrogen receptor, epidermal growth factor receptor and survival. Ann Oncol 1999;10:707-13.
28. Colomer R, Aparicio J, Montero, S, Guzman C, Larrodera L, Cortes-Funes H. Low levels of basic fibroblast factor (bFGF) are associated with a poor prognosis in human breast carcinoma. Br J Cancer 1997;76: 1215-20.
29. Yiangou C, Gomm JJ, Coops RC, et al. Fibroblast growth factor 2 in breast cancer: occurrence and prognostic significance. Br J Cancer 1997; 75:28-33.
30. Hrushesky WJM, Lester B, Lannin D. Circadian coordination of cancer take and metastatic spread. Int J Cancer 1999;83:365-73.
31. Fisher B, Gunduz N, Zheng S, Saffer EA. Fluoresceinated estrone binding by human and mouse breast cancer cells. Cancer Res 1982;42: 540-9.
32. Allen E. The oestrous cycle in the mouse. Am J Anat 1922;30: 297-348.
33. Torossov MT, Hrushesky WJM, Gupta H, Mann G, Vyzula R, Wood PA. Fertility cycle dependent tumor growth non-linearity unmasked. Proc Am Assoc Cancer Res 1995;36:38.
34. Weidner N. Intratumoral microvessel density as a prognostic factor in cancer. Am J Pathol 1995;147:9-19.
35. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992;84:1875-87.
36. You S, Li W, Kobayashi M, Xiong Y, Hrushesky WJM, Wood PA. Creation of a stable mammary tumor cell line that maintains fertility cycle tumor biology of the parent tumor. In Vitro Cell Dev Biol Anim 2004;40: 187-95.
37. Wells WA, Rainer RO, Memoli VA. Basic principles of image processing. Am J Clin Pathol 1992;98:493-501.
38. You S, Yao K, Coo Y. Latency of Epstein-Barr virus and its relationship to nasopharyngeal carcinomas. Zhonghua Zhong Liu Za Zhi 1996;18:23-6.
39. Song CW, Levitt SH. Effect of X irradiation on vascularity of normal tissues and experimental tumor. Radiology 1970;94:445-7.
40. Sands H, Shah SA, Gallagher BM. Vascular volume and permeability of human and murine tumors grown in athymic mice. Cancer Lett 1985; 27:15-21.
41. Bergman MD, Schachter BS, Karelus K, Combatsiaris ER, Garcia T, Nelson JF. Up-regulation of the uterine estrogen receptor and its messenger ribonucleic acid during the mouse estrous cycle: the role of estradiol. Endocrinology 1992;130:1923-30.
42. Michael SD. Plasma prolactin and progesterone during the estrous cycle in the mouse. Proc Soc Exp Biol Med 1976;153:254-7.
43. Song C, Levitt S, Hear K, et al. Vascular endothelial growth factor in premenopausal women-indicator of the best time for breast cancer surgery? Br J Cancer 1998;78:1203-7.
44. Buteau-Lozano H, Ancelin M, Lardeux B, Milanini J, Perrot-Applanat M. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors α and β. Cancer Res 2002;62: 4977-84.
45. Menders P, Beex LV, Tjan-Heijnen VC, et al. The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy. Br J Cancer 2002; 87:772-8.
46. Lu W, Schroit AJ. Vascularization of melanoma by mobilization and remodelling of preexisiting latent vessels to patency. Cancer Res 2005;65: 913-8.
47. Verheul H, Hoekman K, de Bakker SL, et al. Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res 1997;3: 2187-90.
48. Brown-Grant K, Raisman G. Abnormalities in reproductive function associated with the destruction of the suprachiasmatic nuclei in female rats. Proc R Soc Lond B Biol Sci 1977;198:279-96.
49. Miller BH, Olson SL, Turek FW, Levine JE, Horton TH, Takahashi JS. Circadian clock mutation disrupts estrous cyclicity and maintenance of pregnancy. Curr Biol 2004;14:1367-73.
50. Koyanagi S, Kuramoto Y, Nakagawa H, et al. A molecular mechanism regulating circadian expression of vascular endothelial growth factor in tumor cells. Cancer Res 2003;63:7277-83.
51. Nakagawa H, Koyanagi S, Takiguchi T, et al. 24-hour oscillation of mouse methionine aminopeptidase2, a regulator of tumor progression, is regulated by clock gene proteins. Cancer Res 2004;64: 8328-33.
52. Lampl M, Veldhuis JD, Johnson ML. Saltation and stasis: a model of human growth. Science 1992;258:801-3.